Oncolytic Sendai virus-based virotherapy for cancer: recent advances

Many drugs have been developed and optimized for the treatment of cancer; however, it is difficult to completely cure cancer with anticancer drugs alone. Therefore, the development of new therapeutic technologies, in addition to new anticancer drugs, is necessary for more effective oncotherapy. Onco...

Full description

Saved in:
Bibliographic Details
Published inOncolytic virotherapy Vol. 4; pp. 141 - 147
Main Authors Saga, Kotaro, Kaneda, Yasufumi
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2015
Taylor & Francis Ltd
Dove Medical Press
Subjects
Apoptosis
Brain cancer
Cancer therapies
Drug resistance
Genes
Genomes
Health aspects
Immunotherapy
Infections
Medical research
Melanoma
Proteins
Review
RNA viruses
Viruses
Japan
anticancer immunity
cancer therapy
apoptosis
HVJ-E
necroptosis
Online AccessGet full text

Cover

More Information
Summary:Many drugs have been developed and optimized for the treatment of cancer; however, it is difficult to completely cure cancer with anticancer drugs alone. Therefore, the development of new therapeutic technologies, in addition to new anticancer drugs, is necessary for more effective oncotherapy. Oncolytic viruses are one potential new anticancer strategy. Various oncolytic viruses have been developed for safe and effective oncotherapy. Recently, Sendai virus-based oncotherapy has been reported by several groups, and attention has been drawn to its unique anticancer mechanisms, which are different from those of the conventional oncolytic viruses that kill cancer cells by cancer cell-selective replication. Here, we introduce Sendai virus-based virotherapy and its anticancer mechanisms.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2253-1572
2253-1572
DOI:10.2147/OV.S66419